CPR - Anti-A Monoclonal
CPR - Anti-A Monoclonal
2O2O113JIUU EVYTFU
Republic of the Philippines
Department ofHealth
FOOD AND DRUG ADMINISTRATION
FflA,u,,
I (rir 'jrJ ii 'i 4,i iiLrrr:;:i ijr-r,,r.
f illl la);'il\lt-.':,
Civic Drive, Filinvest Corporate Cit_v, Alabang, lVfuntir"ilupr {.lily
Trader
Importer Biosite Medical Instruments Inc. - 512-A Manga St., Juna Subdivision, Matina Crossing 74-A,
Talomo District, Davao City, Davao del Sur
Distributor Biosite Medical Instruments Inc. - 512-A Manga St,, Juna Subdivision, Nlatina Crossing 74-A,
Talomo District, Davao City, Davao del Sur
Approved Use Intended use for the identification of "A" Antigen on human erythrocytes used in slide/tube.
This registration shall be valid for 5 years and shall expire on 5 July 2025 subject to the conditions listed on the
reverse side.
No change in the information, labelling and commercial presentation of this product shall be made during the
effectivity of this registration without approval of this Office.
'Ihis registration is subject to suspension, cancellation or recall should violation of any provisions of R.A. 3720, as
amended, andJor regulations issued thereunder involving the product be committed.
Witness My Hand and Seal of this Office, this 24th day of July, 2020.
o C
IV
DTN :20200213104310
O.R. No :1246754
Amount :P 5,050.00
Date Issued :13 February 2020
/kccp
,' '.r:\,
"',
i; I rDA-0471576
MANDATORY REQUIREMENT :
1. This product must be available only in drugstores, hospitals and other legal outlets.
2. The labelling of each device must state:
a) The date (montUyear) within which to use said device, whenever applicable.
b) The lot or batch number, whenever applicable.
c) Product registration number
d) Name and address of local distributor/importer.
SPECIAI CONDITION
Providsd that nothing in the registration of the product herein granted shall be interpreted or construed as an endorsement
or representation by FDA, that Registrant has the right privilege to the use of the name or brand so registered; Registrant
hereby agree and affirm to indemnify andlor hold FDA free and harmless against any and all third-party claims on
infringement of patent, trademark or industrial design rights arising from the registration of the product(s) listed on the
other side hereof.
)f Jqnx
Next Review Date: September 202 I
tru